Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat

Siddika E Karakas, R. C. LeBoeuf, S. Khilnani, L. Tallapaka, D. Dayananda, K. L C Jen

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase have been approved for treatment of hypercholesterolemia in humans. This class of therapeutic agents, in addition to lowering plasma cholesterol, reduces plasma triglyceride levels. We have investigated the mechanism of triglyceride-lowering effect of lovastatin in the hypertriglyceridemic state by using a rodent model of hypertriglyceridemia and obesity, the Zucker obese (fa/fa) rat. Lovastatin treatment (4 mg/kg), as compared to placebo, caused a 338% reduction in plasma triglyceride (146 ± 5 vs. 494 ± 76 mg/dl), a 58% decrease in total cholesterol (99 ± 13 vs. 156 ± 18 mg/dl), and a 67% reduction in high density lipoprotein (HDL)-cholesterol (69 ± 8 vs. 115 ± 15 mg/dl). The fall seen in plasma triglyceride was due to a decrease in hepatic secretion of very low density lipoproteins (VLDL), determined after blocking the clearance of triglyceride-rich lipoproteins with Triton WR-1339. Lovastatin treatment did not affect either the activities of hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, or malic enzyme, or the activities of the lipolytic enzymes of adipose tissue, lipoprotein lipase, or liver, hepatic triglyceride lipase. Supplementation of mevalonolactone in the diet partially reversed the changes in plasma triglyceride (265 ± 37 vs. 146 ± 5 mg/dl), but not in total or HDL-cholesterol. These data demonstrate that, in the hypertriglyceridemic Zucker rat model, HMG-CoA reductase inhibitors reduce the rate of secretion of VLDL and this effect can be partially reversed by administration of mevalonolactone.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Lipid Research
Volume33
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Zucker Rats
Rats
Oxidoreductases
Animals
Triglycerides
Animal Models
Lovastatin
Plasmas
VLDL Lipoproteins
Liver
HDL Cholesterol
Enzymes
Cholesterol
Lipoprotein Lipase
Glucosephosphate Dehydrogenase
Hypertriglyceridemia
Therapeutics
Nutrition
Hypercholesterolemia
Lipase

Keywords

  • mevalonolactone
  • Triton WR-1339
  • VLDL secretion
  • Zucker fa/fa rat

ASJC Scopus subject areas

  • Endocrinology

Cite this

Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. / Karakas, Siddika E; LeBoeuf, R. C.; Khilnani, S.; Tallapaka, L.; Dayananda, D.; Jen, K. L C.

In: Journal of Lipid Research, Vol. 33, No. 1, 1992, p. 1-7.

Research output: Contribution to journalArticle

Karakas, Siddika E ; LeBoeuf, R. C. ; Khilnani, S. ; Tallapaka, L. ; Dayananda, D. ; Jen, K. L C. / Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. In: Journal of Lipid Research. 1992 ; Vol. 33, No. 1. pp. 1-7.
@article{f4a547c44d244c6b924cde92a03dfab1,
title = "Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat",
abstract = "Inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase have been approved for treatment of hypercholesterolemia in humans. This class of therapeutic agents, in addition to lowering plasma cholesterol, reduces plasma triglyceride levels. We have investigated the mechanism of triglyceride-lowering effect of lovastatin in the hypertriglyceridemic state by using a rodent model of hypertriglyceridemia and obesity, the Zucker obese (fa/fa) rat. Lovastatin treatment (4 mg/kg), as compared to placebo, caused a 338{\%} reduction in plasma triglyceride (146 ± 5 vs. 494 ± 76 mg/dl), a 58{\%} decrease in total cholesterol (99 ± 13 vs. 156 ± 18 mg/dl), and a 67{\%} reduction in high density lipoprotein (HDL)-cholesterol (69 ± 8 vs. 115 ± 15 mg/dl). The fall seen in plasma triglyceride was due to a decrease in hepatic secretion of very low density lipoproteins (VLDL), determined after blocking the clearance of triglyceride-rich lipoproteins with Triton WR-1339. Lovastatin treatment did not affect either the activities of hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, or malic enzyme, or the activities of the lipolytic enzymes of adipose tissue, lipoprotein lipase, or liver, hepatic triglyceride lipase. Supplementation of mevalonolactone in the diet partially reversed the changes in plasma triglyceride (265 ± 37 vs. 146 ± 5 mg/dl), but not in total or HDL-cholesterol. These data demonstrate that, in the hypertriglyceridemic Zucker rat model, HMG-CoA reductase inhibitors reduce the rate of secretion of VLDL and this effect can be partially reversed by administration of mevalonolactone.",
keywords = "mevalonolactone, Triton WR-1339, VLDL secretion, Zucker fa/fa rat",
author = "Karakas, {Siddika E} and LeBoeuf, {R. C.} and S. Khilnani and L. Tallapaka and D. Dayananda and Jen, {K. L C}",
year = "1992",
language = "English (US)",
volume = "33",
pages = "1--7",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat

AU - Karakas, Siddika E

AU - LeBoeuf, R. C.

AU - Khilnani, S.

AU - Tallapaka, L.

AU - Dayananda, D.

AU - Jen, K. L C

PY - 1992

Y1 - 1992

N2 - Inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase have been approved for treatment of hypercholesterolemia in humans. This class of therapeutic agents, in addition to lowering plasma cholesterol, reduces plasma triglyceride levels. We have investigated the mechanism of triglyceride-lowering effect of lovastatin in the hypertriglyceridemic state by using a rodent model of hypertriglyceridemia and obesity, the Zucker obese (fa/fa) rat. Lovastatin treatment (4 mg/kg), as compared to placebo, caused a 338% reduction in plasma triglyceride (146 ± 5 vs. 494 ± 76 mg/dl), a 58% decrease in total cholesterol (99 ± 13 vs. 156 ± 18 mg/dl), and a 67% reduction in high density lipoprotein (HDL)-cholesterol (69 ± 8 vs. 115 ± 15 mg/dl). The fall seen in plasma triglyceride was due to a decrease in hepatic secretion of very low density lipoproteins (VLDL), determined after blocking the clearance of triglyceride-rich lipoproteins with Triton WR-1339. Lovastatin treatment did not affect either the activities of hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, or malic enzyme, or the activities of the lipolytic enzymes of adipose tissue, lipoprotein lipase, or liver, hepatic triglyceride lipase. Supplementation of mevalonolactone in the diet partially reversed the changes in plasma triglyceride (265 ± 37 vs. 146 ± 5 mg/dl), but not in total or HDL-cholesterol. These data demonstrate that, in the hypertriglyceridemic Zucker rat model, HMG-CoA reductase inhibitors reduce the rate of secretion of VLDL and this effect can be partially reversed by administration of mevalonolactone.

AB - Inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase have been approved for treatment of hypercholesterolemia in humans. This class of therapeutic agents, in addition to lowering plasma cholesterol, reduces plasma triglyceride levels. We have investigated the mechanism of triglyceride-lowering effect of lovastatin in the hypertriglyceridemic state by using a rodent model of hypertriglyceridemia and obesity, the Zucker obese (fa/fa) rat. Lovastatin treatment (4 mg/kg), as compared to placebo, caused a 338% reduction in plasma triglyceride (146 ± 5 vs. 494 ± 76 mg/dl), a 58% decrease in total cholesterol (99 ± 13 vs. 156 ± 18 mg/dl), and a 67% reduction in high density lipoprotein (HDL)-cholesterol (69 ± 8 vs. 115 ± 15 mg/dl). The fall seen in plasma triglyceride was due to a decrease in hepatic secretion of very low density lipoproteins (VLDL), determined after blocking the clearance of triglyceride-rich lipoproteins with Triton WR-1339. Lovastatin treatment did not affect either the activities of hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, or malic enzyme, or the activities of the lipolytic enzymes of adipose tissue, lipoprotein lipase, or liver, hepatic triglyceride lipase. Supplementation of mevalonolactone in the diet partially reversed the changes in plasma triglyceride (265 ± 37 vs. 146 ± 5 mg/dl), but not in total or HDL-cholesterol. These data demonstrate that, in the hypertriglyceridemic Zucker rat model, HMG-CoA reductase inhibitors reduce the rate of secretion of VLDL and this effect can be partially reversed by administration of mevalonolactone.

KW - mevalonolactone

KW - Triton WR-1339

KW - VLDL secretion

KW - Zucker fa/fa rat

UR - http://www.scopus.com/inward/record.url?scp=0026540899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026540899&partnerID=8YFLogxK

M3 - Article

C2 - 1552226

AN - SCOPUS:0026540899

VL - 33

SP - 1

EP - 7

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 1

ER -